SCHEMBL5544099

SCHEMBL5544099

[CH2]CC(=O)N1CCN(C(=O)OCCc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.48
L3MBTL1 Q9Y468 2/20 0.44
ME2 P23368 1/20 0.44
ME1 P48163 1/20 0.44
ME3 Q16798 1/20 0.44
HTR2A P28223 3/20 0.44
OPRM1 P35372 3/20 0.44
HTR1A P08908 2/20 0.44
DRD4 P21917 2/20 0.44
HRH1 P35367 2/20 0.44
ADORA3 P0DMS8 2/20 0.44
HTR7 P34969 2/20 0.44
CACNA1F O60840 1/20 0.44
DRD2 P14416 1/20 0.44
DRD5 P21918 1/20 0.44
HRH2 P25021 1/20 0.44
ADRA1D P25100 1/20 0.44
HTR2C P28335 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536923 0.90 HRH3 (0.52) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5544923 0.86 HRH3 (0.48) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5536352 0.78 L3MBTL1 (0.70) L3MBTL1SIGMAR1ALDH1A1MDH1MDH2
SCHEMBL5542452 0.78 HRH3 (0.48) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5535703 0.77 TACR1 (0.48) HTR2ACNR1MEN1KMT2ASIGMAR1
SCHEMBL5545275 0.76 HRH3 (0.46) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5545185 0.75 ENPP2 (0.46) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5538480 0.74 ENPP2 (0.45) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5537103 0.74 ENPP2 (0.49) HRH3L3MBTL1ME2ME1ME3
SCHEMBL5543639 0.72 ENPP2 (0.46) HRH3L3MBTL1HPGDSMN1; SMN2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HRH3 420/4885L3MBTL1 1931/4885ME2 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.